Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant
Active, not recruiting · Not applicable · NCT06163404
Conditions: Nasal Septal Deviation, Nasal Airway Obstruction
At a glance
- Research payments reported, 2025
- $252,157
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 102
About the trial
- Sponsor
- Spirair, Inc
- Tested
- Implantation of Spirair Nasal Device using the Spirair delivery system. (device)
- Dates
- Started 2023-11-01; completion 2027-06
- Results posted
- Not yet
Pilot study of bioabsorbable implant and delivery device for correction of septal deviation.
From ClinicalTrials.gov, last updated 2026-03-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Spirair, Inc. reported $252,157 in research payments for this study in 2025 (12 payments).
Products named: Septalign
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael J. Sillers, MD ENT (Otolaryngology) · Birmingham, AL
- Steven E. Davis, M.D. ENT (Otolaryngology) · Torrance, CA
- Adil A. Fatakia, M.D. ENT (Otolaryngology) · Marrero, LA
- Nora W. Perkins, M.D. ENT (Otolaryngology) · Albany, NY
- David M. Yen, M.D. Specialist · Bethlehem, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Specialty Physicians Associates $105,966
- Breathe Clear Institute $94,901
- Tandem Clinical Research, LLC $28,910
- Albany Ent &allergy Services PC $14,985
- Alabama Nasal and Sinus Center $7,395
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.